The Challenge of Managing Bladder Cancer and Upper Tract Urothelial Carcinoma: A Review with Treatment Recommendations from the Spanish Oncology Genitourinary Group (SOGUG)
Por:
Font, A, Luque, R, Villa, J, Domenech, M, Vazquez, S, Gallardo, E, Virizuela, J, Beato, C, Morales-Barrera, R, Gelabert, A, Macia, S, Puente, J, Rubio, G, Maldonado, X, Perez-Valderrama, B, Pinto, A, Calvo, O, Grande, E, Garde-Noguera, J, Fernandez-Parra, E and Arranz, J
Publicada:
1 feb 2019
Resumen:
Bladder cancer is the fourth most common cancer in men and the ninth most common in women in the Western world. The management of bladder carcinoma requires a multidisciplinary approach. Optimal treatment depends on several factors, including histology, stage, patient status, and possible comorbidities. Here we review recent findings on the treatment of muscle-invasive bladder carcinoma, advanced urothelial carcinoma, upper tract urothelial carcinoma, non-urothelial carcinoma, and urologic complications arising from the disease or treatment. In addition, we present the recommendations of the Spanish Oncology Genitourinary Group for the treatment of these diseases, based on a focused analysis of clinical management and the potential of current research, including recent findings on the potential benefit of immunotherapy. In recent years, whole-genome approaches have provided new predictive biomarkers and promising molecular targets that could lead to precision medicine in bladder cancer. Moreover, the involvement of other specialists in addition to urologists will ensure not only appropriate therapeutic decisions but also adequate follow-up for response evaluation and management of complications. It is crucial, however, to apply recent molecular findings and implement clinical guidelines as soon as possible in order to maximize therapeutic gains and improve patient prognosis.
Filiaciones:
Font, A:
Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol, B ARGO Grp, Med Oncol Serv, Ctra Canyet S-N, Badalona 08916, Spain
Luque, R:
Hosp Univ Virgen de las Nieves, Med Oncol Serv, Granada, Spain
Villa, J:
Hosp Gen Univ Ciudad Real, Med Oncol Serv, Ciudad Real, Spain
Domenech, M:
Hosp Fundacio Althaia, Med Oncol Serv, Manresa, Spain
Vazquez, S:
Hosp Univ Lucus Augusti, EOXI Lugo, Med Oncol Serv, Cervo E Monforte, Spain
Gallardo, E:
Univ Autonoma Barcelona, Parc Tauli Hosp Univ, Inst Invest Innovacio Parc Tauli I3PT, Dept Oncol, Sabadell, Spain
Virizuela, J:
Hosp Virgen de la Macarena, Med Oncol Serv, Seville, Spain
Beato, C:
Hosp Virgen de la Macarena, Med Oncol Serv, Seville, Spain
Morales-Barrera, R:
Univ Autonoma Barcelona, VHIO, Hosp Univ Vall dHebron, Med Oncol Serv, Barcelona, Spain
Gelabert, A:
Hosp del Mar, Dept Urol, Barcelona, Spain
Macia, S:
CRO Pivotal, Dept Med Oncol, Madrid, Spain
Puente, J:
Hosp Clin San Carlos, CIBERONC, Inst Invest Sanitaria Hosp Clin San Carlos IdISSC, Dept Med Oncol, Madrid, Spain
Rubio, G:
Hosp Univ Fdn Jimenez Diaz, Med Oncol Serv, Madrid, Spain
Maldonado, X:
Hosp Univ Vall dHebron, Radiat Oncol Serv, Barcelona, Spain
Perez-Valderrama, B:
Hosp Univ Virgen del Rocio, Med Oncol Serv, Seville, Spain
Pinto, A:
Hosp Univ La Paz, Med Oncol Serv, Madrid, Spain
Calvo, O:
Complejo Hosp Univ Ourense, Med Oncol Serv, Orense, Spain
Grande, E:
MD Anderson Canc Ctr, Med Oncol, Madrid, Spain
:
Hosp Arnau Vilanova, Med Oncol Serv, Valencia, Spain
Fernandez-Parra, E:
Hosp Univ Nuestra Senora de Valme, Med Oncol Serv, Seville, Spain
Arranz, J:
Hosp Gen Univ Gregorio Maranon, Med Oncol Serv, Madrid, Spain
|